Free press releases distribution network?

Agency / Source: Synergy Research Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Clinical Trials in Russia – First Issue of the SynRG Orange Book Published - On April 25, 2007, the first issue of the Orange Paper – the first analytical review on market of clinical trials in Russia – was officially presented - SynRG-Pharm.com
Clinical Trials in Russia – First Issue of the SynRG Orange Book Published

 

PRZOOM - /newswire/ - Moscow, Russia, 2007/05/14 - On April 25, 2007, the first issue of the Orange Paper – the first analytical review on market of clinical trials in Russia – was officially presented - SynRG-Pharm.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The strategic goals of Synergy Research Group, a Russia-based emerging CRO, are formation of a civilized market of clinical trials in Russia, raising the country’s research attractiveness for foreign sponsors, and exoneration of clinical trials in Russian public opinion.

The Orange Paper – a series of regular reviews of the Russian market of clinical trials – will be the first step in this direction. The reports will be published in Russia both in the electronic and hard-copy form. While the English-language version will be distributed abroad by subscription and on popular websites dedicated to clinical trials, the hard-copy edition is to be distributed at international exhibitions and conferences on clinical trials.

The first issue presents the general overview of the Russian market of clinical trials as for the beginning of 2007. The quarterly publications to follow will elaborate in a more detailed way the subjects tackled in the review: general possibility of conducting clinical trials in Russia, review of the current legislative base, analysis of clinical trials being held in Russia today (by their sponsors, stages and therapeutic fields), rating of the most active foreign and Russian medication developers, review of services and rating of contract research organizations operating in Russia, review of research centers, laboratories, facilities for storage of samples, and other service suppliers for holding clinical trials in Russia.

According to Nikolay Odintsov, the Director General of Synergy Research Group, “the document opens a series of publications meant to provide all the concerned people with objective and unbiased, and (which is the most important) fresh and up-to-date information on the market of clinical trials in Russia”.

Synergy Research Group (SynRG™) is a Russian contract research organization, which has been successfully operating all over Russia and the CIS member-states since 2002. SynRG™ offers a broad range of services for conducting clinical trials for Russian and foreign pharmaceutical and biotechnological companies – from registration of the studies in regulatory authorities to pharmaco-economic surveys. The company has its own storehouse of clinical samples in Moscow, with the total area of 180 square meters. Today, Synergy Research Group is represented in Moscow, Saint-Petersburg, Novosibirsk, Yekaterinburg and Almaty. The company’s headquarters are in Moscow.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Synergy Research Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Clinical Trials in Russia – First Issue of the SynRG Orange Book Published

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Igor Stefanov - SynRG-Pharm.com 
+7 495-253-3453 office[.]synrg-pharm.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Synergy Research Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Synergy Research Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today